Malaria vaccine

R21 anti-malaria vaccine is a game changer: scientist who helped design it reflects on 30 years of research, and what it promises

Retrieved on: 
Thursday, April 25, 2024

Until three years ago nobody had developed a vaccine against any parasitic disease. Now there are two against malaria: the RTS,S and the R21 vaccines. Adrian Hill, director of the Jenner Institute at the University of Oxford and chief investigator for the R21 vaccine, tells Nadine Dreyer why he thinks this is a great era for malaria control.What makes malaria such a difficult disease to beat?Our hominoid predecessors were being infected by malaria parasites tens of millions of years ago, so these parasites had a lot of practice at clever tricks to escape immune systems long before we came along.

Key Points: 


Until three years ago nobody had developed a vaccine against any parasitic disease. Now there are two against malaria: the RTS,S and the R21 vaccines. Adrian Hill, director of the Jenner Institute at the University of Oxford and chief investigator for the R21 vaccine, tells Nadine Dreyer why he thinks this is a great era for malaria control.

What makes malaria such a difficult disease to beat?

  • Our hominoid predecessors were being infected by malaria parasites tens of millions of years ago, so these parasites had a lot of practice at clever tricks to escape immune systems long before we came along.
  • Additionally, the malaria parasite goes through four life cycle stages.
  • Medical researchers have been trying to make malaria vaccines for over 100 years.

How does the R21/Matrix-M vaccine work?

  • An antigen is any substance that causes the body to make an immune response against that substance.
  • We targeted the sporozoites, which is the form that the mosquito inoculates into your skin.
  • Read more:
    Two new malaria vaccines are being rolled out across Africa: how they work and what they promise

A child dies every minute from malaria in Africa. Why are children more susceptible than adults?

  • The age you’re most likely to die of malaria in Africa is when you are one year old.
  • For the first six months you are protected largely by your mother’s immunity and the antibodies she transfers during pregnancy.
  • Without malaria, children would be healthier in general — the disease makes you susceptible to other infections.

What about the pace of vaccine rollouts?

  • We’ve been disappointed that it’s taken more than six months to roll out the R21 vaccine since it was approved in October last year.
  • Compare that to a COVID-19 vaccine from Oxford and AstraZeneca that was approved on New Year’s Eve 2020 and rolled out in several countries the very next week.

How big a role will vaccines have in the fight to eradicate malaria?

  • Nobody is quite sure how many of the older tools such as insecticides and bed nets we need to carry on with.
  • Anti-malaria medication only lasts for days and parasites are building up resistance against these drugs as well.
  • There are about 40 million children born every year in malaria areas in Africa who would benefit from a vaccine.
  • The Serum Institute of India, our manufacturing and commercial partner, can produce hundreds of millions of doses each year.


Adrian Hill receives funding from government and charitable funders of malaria vaccine development. He has received funding awarded to the University of Oxford from the Serum Institute of India to support clinical trials of the R21/Matrix-M vaccine. He may benefit for a share of any royalty stream to Oxford University from the vaccine.

AHF: Newly Approved Malaria Vaccine Is a Win for Global Health

Retrieved on: 
Thursday, October 5, 2023

AIDS Healthcare Foundation (AHF) applauds the World Health Organization’s (WHO) recommendation of a new malaria vaccine, R21/Matrix-M, for preventing malaria, which disproportionately affects African children.

Key Points: 
  • AIDS Healthcare Foundation (AHF) applauds the World Health Organization’s (WHO) recommendation of a new malaria vaccine, R21/Matrix-M, for preventing malaria, which disproportionately affects African children.
  • The affordable and easily deployable vaccine is a welcome step towards vaccinating our world, and Global North countries should help fund the vaccine for equitable distribution.
  • “Once deployed, the new vaccine will help prevent more than 600,000 annual deaths due to malaria, which affects children under age five in Africa most.
  • Now, we must all work together to deliver on the promise this vaccine offers – saving the millions of lives affected by malaria.”

GHIT Fund Announces New Investments: A Total of 2.3 Billion Yen in Drugs for Malaria, Tuberculosis, Chagas Disease and Visceral Leishmaniasis, Vaccine for Malaria and Diagnostics for Tuberculosis

Retrieved on: 
Wednesday, March 31, 2021

Targeted vaccination of individuals in high transmission areas promise an immediate and effective reduction in the number of malaria cases.

Key Points: 
  • Targeted vaccination of individuals in high transmission areas promise an immediate and effective reduction in the number of malaria cases.
  • Although a TBV would not directly prevent immunized individuals from developing the disease, it has a clear, delayed clinical benefit for the population.
  • Moreover, a TBV could provide effective means to prevent the spread of antimalarial drug-resistant parasites, and parasites that break through the most advanced malaria vaccine (Mosquirix) to date.
  • Thus, the development of new TBVs is one of the research priorities for a cost-effective intervention that can directly support the malaria eradication effort.

EU Malaria Fund: Sanaria receives substantial investment into its proprietary malaria platform

Retrieved on: 
Sunday, November 15, 2020

The EU Malaria Fund has been initiated by kENUP Foundation and is managed by a General Partner under the supervision of Investitionsbank Berlin.

Key Points: 
  • The EU Malaria Fund has been initiated by kENUP Foundation and is managed by a General Partner under the supervision of Investitionsbank Berlin.
  • On November 13, 2020, Sanaria received 12.9M for the development of two malaria vaccines, one malaria prophylactic, as well as an initial proof-of-concept for an oral SARS-CoV-2 vaccine.
  • Sanarias PfSPZ Vaccine is a radiation-attenuated whole-organism vaccine, meaning it is a weakened form of the parasite that causes malaria.
  • Holm Keller, Co-Managing Director of EUMF and Chairman of kENUP Foundation said: Sanaria has developed one of the most advanced malaria vaccine candidates worldwide.

Novavax and Serum Institute of India Announce Development and Commercial Collaboration

Retrieved on: 
Thursday, August 6, 2020

As the worlds largest vaccine manufacturer in terms of doses delivered, Serum Institute is the ideal partner to advance NVXCoV2373 throughout India and the LMIC countries.

Key Points: 
  • As the worlds largest vaccine manufacturer in terms of doses delivered, Serum Institute is the ideal partner to advance NVXCoV2373 throughout India and the LMIC countries.
  • For LMICs and India, Novavax and SIIPL are partnering on clinical development, co-formulation, filling and finishing and commercialization of NVX-CoV2373.
  • Novavax will provide to SIIPL both vaccine antigen and MatrixM adjuvant, and Novavax and SIIPL are in discussions to have SIIPL manufacture vaccine antigen in India.
  • Given our experience with Novavax on the development of a malaria vaccine, we know the power of their vaccine technologies, said Adar Poonawalla, Chief Executive Officer of Serum Institute of India.

OncoSec's Novel COVID-19 Vaccine Candidate Featured in 'Straight Talk' Program by NBC TV in Portland, Oregon

Retrieved on: 
Monday, July 13, 2020

You can watch the full episode and read the article here: https://www.kgw.com/article/entertainment/television/programs/straight-t...

Key Points: 
  • You can watch the full episode and read the article here: https://www.kgw.com/article/entertainment/television/programs/straight-t...
    OncoSec and researchers at Providence Cancer Institute previously announced a collaboration to conduct a first-in-human trial of OncoSec's CORVax12 vaccine candidate.
  • CORVax12 is designed to drive a coordinated vaccine response, capable of drawing upon the innate, adaptive humoral, and adaptive cellular arms.
  • Researchers believe this multi-pronged innate, adaptive and cellular immune response is likely to be important in generating a robust anti-viral response.
  • OncoSec's lead product candidate, TAVO, enables the intratumoral delivery of DNA-based interleukin-12 or IL-12, a naturally occurring protein with immune-stimulating functions.

Intravacc to In-license CimCure's iBoost Technology, Expanding its Vaccine Platform Portfolio

Retrieved on: 
Wednesday, July 1, 2020

This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.

Key Points: 
  • This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.
  • iBoost is currently applied to elicit antibody responses against the tumor vasculature, a strategy that conquers the problem of drug resistance.
  • By using the patented iBoost technology, Intravacc and CimCure are also involved in the joint development of a COVID-19 vaccine.
  • Intravacc also has its own proprietary vaccine platform, and established state-of-the-art research and (GMP) production facilities.

Intravacc to In-license CimCure's iBoost Technology, Expanding its Vaccine Platform Portfolio

Retrieved on: 
Wednesday, July 1, 2020

This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.

Key Points: 
  • This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.
  • iBoost is currently applied to elicit antibody responses against the tumor vasculature, a strategy that conquers the problem of drug resistance.
  • By using the patented iBoost technology, Intravacc and CimCure are also involved in the joint development of a COVID-19 vaccine.
  • Intravacc also has its own proprietary vaccine platform, and established state-of-the-art research and (GMP) production facilities.

Ocean Biomedical Announces Groundbreaking Malaria Vaccine Discovery

Retrieved on: 
Wednesday, April 22, 2020

PROVIDENCE, R.I., April 22, 2020 /PRNewswire/ --Ocean Biomedical is pleased to announce a groundbreaking discovery in the global effort to eradicate malaria.

Key Points: 
  • PROVIDENCE, R.I., April 22, 2020 /PRNewswire/ --Ocean Biomedical is pleased to announce a groundbreaking discovery in the global effort to eradicate malaria.
  • "Dr. Kurtis' team's discovery of PfGARP is a major advance toward developing a vaccine for this devastating disease, and Ocean Biomedical is committed to developing and delivering this vaccine."
  • Ocean Biomedical is developing Dr. Kurtis' discovery to accelerate the timetable for clinical availability of this new vaccine and related medicines.
  • "This malaria vaccine platform has generated one of the most exciting vaccine candidates for treating malaria in the world.

Global malaria vaccine market is expected to grow with a CAGR of 34% over the forecast period from 2019-2025

Retrieved on: 
Friday, March 13, 2020

The report on the global malaria vaccine market provides qualitative and quantitative analysis for the period from 2017 to 2025.

Key Points: 
  • The report on the global malaria vaccine market provides qualitative and quantitative analysis for the period from 2017 to 2025.
  • The report predicts the global malaria vaccine market to grow with a CAGR of 34% over the forecast period from 2019-2025.
  • The study on malaria vaccine market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.
  • The report on malaria vaccine market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global malaria vaccine market over the period of 2017 to 2025.